Today’s Research Reports on GeneNews, Cipher Pharmaceuticals, GLG Life Tech and Trillium Therapeutics

NEW YORK, NY / ACCESSWIRE / May 30, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

GeneNews Ltd.
https://rdinvesting.com/news/?ticker=GEN.TO

Cipher Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=CPH.TO

GLG Life Tech Corporation
https://rdinvesting.com/news/?ticker=GLG.TO

Trillium Therapeutics Inc.
https://rdinvesting.com/news/?ticker=TRIL.TO

GeneNews’ stock had no change Tuesday, to close the day at $0.075. The stock recorded a trading volume of 95,000 shares, which was below its three months average volume of 240,450 shares. In the last year, GeneNews’ shares have traded in a range of 0.07 – 0.24. The stock is currently trading 68.75% below its 52 week high. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $0.088 is below its 200-day moving average of $0.124. Shares of GeneNews have fallen approximately 65.22 percent year-to-date.

Access RDI’s GeneNews Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=GEN.TO

On Tuesday, shares of Cipher Pharmaceuticals recorded a trading volume of 23,177 shares, which was below the three months average volume of 58,293 shares. The stock ended the day 0.87% lower at 3.42. The stock is currently trading 40.52% below its 52-week high with a 52-week trading range of 3.30 – 5.75. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $3.87 is below its 200-day moving average of $4.22. Shares of Cipher Pharmaceuticals are trading at a Price to Earnings ratio of 13.79. Shares of Cipher Pharmaceuticals have fallen approximately 30.20 percent year-to-date.

Access RDI’s Cipher Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CPH.TO

GLG Life Tech’s stock moved 3.16% lower Tuesday, to close the day at $0.92. The stock recorded a trading volume of 16,600 shares, which was above its three months average volume of 5,185 shares. In the last year, GLG Life Tech’s shares have traded in a range of 0.40 – 1.60. The share price has gained 130.00% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $1.01 is below its 200-day moving average of $1.12. Shares of GLG Life Tech have fallen approximately 20 percent year-to-date.

Access RDI’s GLG Life Tech Corporation Research Report at:
https://rdinvesting.com/news/?ticker=GLG.TO

On Tuesday, shares of Trillium Therapeutics recorded a trading volume of 1,900 shares, which was below the three months average volume of 5,409 shares. The stock ended the day 2.79% lower at 7.67. The share price has gained 45.82% from its 52-week low with a 52-week trading range of 5.26 – 16.80. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $8.26 is below its 200-day moving average of $9.86. Shares of Trillium Therapeutics have fallen approximately 15.71 percent year-to-date.

Access RDI’s Trillium Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TRIL.TO

Our Actionable Research on GeneNews Ltd. (TSX :GEN.TO), Cipher Pharmaceuticals Inc. (TSX :CPH.TO), GLG Life Tech Corporation (TSX :GLG.TO) and Trillium Therapeutics Inc. (TSX :TRIL.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 501177